肾移植术后巨细胞病毒感染的诊断与防治进展

赵奇; 廖贵益

doi:10.3969/j.issn.1674-7445.2014.06.015

肾移植术后巨细胞病毒感染的诊断与防治进展

doi: 10.3969/j.issn.1674-7445.2014.06.015

赵奇,
廖贵益^,

230022 合肥, 安徽医科大学第一附属医院泌尿外科

基金项目:

国家重点专科建设项目卫办医政函[2012]649号

详细信息

通讯作者:
廖贵益, Email:liaoguiyi2@sina.com

中图分类号: R617
计量
- 文章访问数: 196
- HTML全文浏览量: 191
- PDF下载量: 12
- 被引次数: 0
出版历程
- 收稿日期: 2014-08-20
- 网络出版日期: 2021-01-19
- 刊出日期: 2014-11-15

摘要

- 肾移植 /
- 巨细胞病毒 /
- 低基质磷酸化蛋白 /
- 基质表层蛋白

HTML全文

参考文献(20)

[1]	Smith MG. Propagation in tissue cultures of a cytopathogenic virus from human salivary gland virus (SGV) disease[J]. Proc Soc Exp Biol Med, 1956, 92(2):424-430. doi: 10.3181/00379727-92-22498
[2]	Yu X, Shah S, Lee M, et al. Biochemical and structural characterization of the capsid-bound tegument proteins of human cytomegalovirus[J].J Struct Biol, 2011, 174(3):451-460. doi: 10.1016/j.jsb.2011.03.006
[3]	Asberg A, Jardine AG, Bignamini AA, et al. Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients[J]. Am J Transplant, 2010, 10(8) : 1881-1888. doi: 10.1111/ajt.2010.10.issue-8
[4]	Heiske A, Roettger Y, Bacher M. Cytomegalovirus upregulates vascular endothelial growth factor and its second cellular kinase domain receptor in human fibroblasts[J]. Viral Immunol, 2012, 25(5):360-367. doi: 10.1089/vim.2012.0028
[5]	Fornara O, Odeberg J, Khan Z, et al. Human cytomegalovirus particles directly suppress CD4 T-lymphocyte activation and proliferation[J]. Immunobiology, 2013, 218(8):1034-1040. doi: 10.1016/j.imbio.2013.01.002
[6]	De Keyzer K, Van Laecke S, Peeters P, et al. Human cytomegalovirus and kidney transplantation: a clinician's update[J]. Am J Kidney Dis, 2011, 58(1):118-126. doi: 10.1053/j.ajkd.2011.04.010
[7]	Cordero E, Casasola C, Ecarma R, et al. Cytomegalovirus disease in kidney transplant recipients: incidence, clinical profile, and risk factors[J]. Transplant Proc, 2012, 44(3):694-700. doi: 10.1016/j.transproceed.2011.11.053
[8]	Kute VB, Vanikar AV, Shah PR, et al. Post-renal transplant cytomegalovirus infection: study of risk factors[J]. Transplant Proc, 2012, 44(3):706-709. doi: 10.1016/j.transproceed.2011.12.025
[9]	Reischig T. Cytomegalovirus-associated renal allograft rejection: new challenges for antiviral preventive strategies[J]. Expert Rev Anti Infect Ther, 2010, 8(8):903-910. doi: 10.1586/eri.10.63
[10]	Faure-Della Corte M, Samot J, Garrigue I, et al. Variability and recombination of clinical human cytomegalovirus strains from transplantation recipients[J]. J Clin Virol, 2010, 47(2):161-169. doi: 10.1016/j.jcv.2009.11.023
[11]	Crough T, Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside[J]. Clin Microbiol Rev, 2009, 22(1):76-98, table of contents. doi: 10.1128/CMR.00034-08
[12]	谭湘芳, 罗志刚, 王毅, 等. CMV-PP65抗原检测在预防肾移植术后巨细胞病毒感染的临床价值[J].中南医学科学杂志, 2013, 41(6):570-571, 626. Tan XF, Luo ZG, Wang Y, et al. The clinical value of CMV-PP65 antigen detection in the prevention of cytomegalovirus infection after renal transplantation[J]. Med Sci J Central South China, 2013, 41(6):570-571, 626.
[13]	Lee S, Park JB, Kim EY, et al. Monitoring of cytomegalovirus-specific CD8⁺ T-cell response with major histocompatibility complex pentamers in kidney transplant recipients[J]. Transplant Proc, 2011, 43(7):2636-2640. doi: 10.1016/j.transproceed.2011.05.051
[14]	Kotton CN. Management of cytomegalovirus infection in solid organ transplantation[J]. Nat Rev Nephrol, 2010, 6(12):711-721. doi: 10.1038/nrneph.2010.141
[15]	Razonable RR. Immune-based therapies for cytomegalovirus infection[J]. Immunotherapy, 2010, 2(1):117-130. doi: 10.2217/imt.09.82
[16]	Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients[J]. Am J Transplant, 2010, 10(5):1228-1237. doi: 10.1111/ajt.2010.10.issue-5
[17]	Humar A, Limaye AP, Blumberg EA, et al. Extended valganciclovir prophylaxis in D+/R-kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study[J]. Transplantation, 2010, 90(12):1427-1431. doi: 10.1097/TP.0b013e3181ff1493
[18]	Helanterä I, Kyll nen L, Lautenschlager I, et al. Primary CMV infections are common in kidney transplant recipients after 6 months valganciclovir prophylaxis[J]. Am J Transplant, 2010, 10(9):2026-2032. doi: 10.1111/j.1600-6143.2010.03225.x
[19]	Humar A, Snydman D, AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients[J]. Am J Transplant, 2009, 9(Suppl 4):S78-S86. http://cn.bing.com/academic/profile?id=1966858455&encoded=0&v=paper_preview&mkt=zh-cn
[20]	白纪民, 李浩, 张晓明, 等. 肾移植术后巨细胞病毒感染的危险因素分析和血清甘露聚糖结合凝集素的预测价值[J].器官移植, 2013, 4(2):79-83. http://www.cnki.com.cn/Article/CJFDTOTAL-QGYZ201302006.htm Bai JM, Li H, Zhang XM, et al. Risk factors of cytomegalovirus infection and the predictive value of mannose-binding lectin after renal transplantation[J]. Organ Transplant, 2013, 4(2):79-83. http://www.cnki.com.cn/Article/CJFDTOTAL-QGYZ201302006.htm